Regulated information

Q3 2011 Sales

Vétoquinol achieved Q3 2011 sales of €68.4 million, in line with the previous year.

Jacques du Puy appointed Vétoquinol Managing Director

Lure (France), October 12, 2011 – The Vétoquinol Group announces the appointment
of Jacques du Puy as Managing Director.

Forcyl®: european launch of new drug

Lure (France), September 29, 2011 – Vétoquinol announces the European launch of Forcyl®, a new drug based on 16% concentrated marbofloxacin allowing the treatment of cattle respiratory infections with a single injection.

Vétoquinol continues to develop its product ranges and enters the brazilian market

Lure (France), August 30, 2011 – The Vetoquinol Board Meeting of August 29, 2011 reviewed the Group’s business and approved the financial statements for the first half 2011.

International expansion and new product launches

Lure (France), July 19, 2011 – Vétoquinol Group sales rose to €139.7 million in the first six months of 2011.

European launch of new Nsaid Cimalgex®

Lure (France), June 14, 2011 – Vetoquinol announces the European launch of CIMALGEX®, a new treatment for pain and inflammation in dogs.

VÉTOQUINOL enters the brazilian Market

Lure (France), June 7, 2011 – Vetoquinol announces the acquisition of 100% of the equity of Farmagricola SA in Brazil.

2010 Activity Report

P_06 VÉTOQUINOL’S PROUD HISTORY
<br>
P_12 SPOTLIGHT ON INNOVATION
<br>
P_18 AN ONGOING DAILY COMMITMENT
TO VETERINARIANS
<br>
P_24 AN INTERNATIONAL COMPANY
MAINTAINING A LOCAL PRESENCE
IN GLOBAL MARKETS
<br>
P_28 GOVERNANCE AND KEY FIGURES

Reference document 2010

Reference document 2010

Vetoquinol publishes its registration document and its annual financial report relative to fiscal year 2010 (french version)

The registration document of Vétoquinol relative to fiscal year 2010, including the annual financial report relative to fiscal year 2010, was registered with the Autorité des marchés financiers (“the AMF”) on April 18th, 2011.